Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
4.09
Dollar change
-0.25
Percentage change
-5.76
%
Index- P/E- EPS (ttm)-2.46 Insider Own34.72% Shs Outstand4.91M Perf Week-10.70%
Market Cap19.84M Forward P/E- EPS next Y-1.94 Insider Trans0.00% Shs Float3.17M Perf Month-20.12%
Income-12.47M PEG- EPS next Q-0.96 Inst Own1.37% Short Float2.16% Perf Quarter23.94%
Sales0.00M P/S- EPS this Y-32.52% Inst Trans-29.81% Short Ratio0.05 Perf Half Y8.52%
Book/sh3.40 P/B1.20 EPS next Y40.49% ROA-44.29% Short Interest0.07M Perf Year-27.99%
Cash/sh4.62 P/C0.88 EPS next 5Y- ROE-64.89% 52W Range2.89 - 7.60 Perf YTD10.64%
Dividend Est.- P/FCF- EPS past 5Y69.13% ROI-74.13% 52W High-46.18% Beta-0.24
Dividend TTM- Quick Ratio5.54 Sales past 5Y0.00% Gross Margin- 52W Low41.58% ATR (14)0.41
Dividend Ex-Date- Current Ratio3.78 EPS Y/Y TTM97.69% Oper. Margin0.00% RSI (14)39.75 Volatility6.96% 8.89%
Employees6 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price36.50
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q28.87% Payout- Rel Volume0.02 Prev Close4.34
Sales Surprise- EPS Surprise0.00% Sales Q/Q- EarningsMar 28 BMO Avg Volume1.36M Price4.09
SMA20-18.02% SMA50-11.75% SMA2002.40% Trades Volume34,056 Change-5.76%
Date Action Analyst Rating Change Price Target Change
Jun-15-20Initiated H.C. Wainwright Buy $20
Mar-28-24 08:01AM
Mar-13-24 08:01AM
Mar-04-24 08:01AM
Feb-29-24 08:01AM
Feb-12-24 08:01AM
08:01AM Loading…
Feb-01-24 08:01AM
Jan-18-24 08:01AM
Jan-09-24 08:30AM
Jan-02-24 08:01AM
Dec-28-23 08:45AM
Dec-19-23 08:43AM
Dec-15-23 08:35AM
Dec-12-23 01:02PM
Dec-01-23 08:31AM
Nov-13-23 04:05PM
08:05AM Loading…
Nov-06-23 08:05AM
Oct-17-23 08:01AM
Sep-15-23 08:01AM
Aug-14-23 08:01AM
Aug-09-23 04:05PM
Aug-03-23 08:01AM
Aug-02-23 08:01AM
Jun-27-23 08:01AM
Jun-13-23 08:01AM
May-12-23 08:00AM
May-02-23 08:01AM
Apr-03-23 08:00AM
Mar-30-23 04:40PM
Jan-18-23 08:00AM
Nov-08-22 04:05PM
09:15AM Loading…
Nov-04-22 09:15AM
Sep-29-22 08:30AM
Sep-15-22 08:30AM
Sep-12-22 09:15AM
May-06-22 08:00AM
Apr-01-22 08:00AM
Mar-15-22 08:00AM
Jan-28-22 04:30PM
Nov-15-21 08:00AM
Nov-04-21 08:00AM
Oct-13-21 08:00AM
Oct-05-21 01:13PM
Oct-01-21 08:00AM
Sep-03-21 11:27AM
Aug-16-21 08:00AM
Jul-12-21 08:30AM
May-17-21 05:02PM
Apr-15-21 04:52PM
Mar-24-21 08:00AM
Mar-05-21 08:30AM
Jan-21-21 04:05PM
Jan-19-21 08:00AM
Jan-06-21 08:30AM
Dec-21-20 05:08AM
Nov-13-20 04:30PM
Sep-02-20 08:30AM
Aug-11-20 03:00PM
Jun-16-20 04:05PM
May-26-20 08:30AM
May-20-20 04:29PM
Apr-21-20 08:30AM
Apr-16-20 04:22PM
Apr-14-20 09:15AM
Mar-31-20 11:04AM
Mar-30-20 04:30PM
Jan-13-20 09:00AM
Jan-10-20 05:00PM
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.